Big pharma is at a crossroads, as J&J, Merck and others prepare to lose heaps of revenue from blockbuster drugs - CNBC


1/28/2024

Big pharma is at a crossroads, as J&J, Merck and others prepare to lose heaps of revenue from blockbuster drugs  CNBCHow big pharma is king of the hill in M&A  Yahoo FinanceThe Twists and Turns in Biopharma Dealmaking: 2024 Trends  Pharmaceutical ExecutiveCooley's 2023 Life Sciences M&A Year in Review: Potent Mix of Creativity and Resilience Spurs Activity Heading Into 2024  JD SupraTop 10 blockbuster drugs that will become off-patent in 2024  MSN...

Original

Categories: Drugs | Financial | Health | Revenue

Tags: big | cnbc | drugs | hill | king | life | review | turns | year



Let us know what you think!

Click on a star to rate it!

Average rating 0 / 5. Vote count: 0

No votes so far! Be the first to rate this post.

Leave a Comment

Scroll back to top